Relmada officer granted 828,000 stock appreciation rights at $4.06
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Rights | 828,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Relmada Therapeutics (RLMD) report in this Form 4?
The company reported that an officer received 828,000 stock appreciation rights12/12/2025
What is the exercise price and term of the new stock appreciation rights at Relmada Therapeutics (RLMD)?
The stock appreciation rights have an exercise price of $4.0612/12/203503/12/2026
How do the Relmada Therapeutics (RLMD) stock appreciation rights vest for this officer?
The stock appreciation rights vest in 16 equal quarterly installmentsMarch 12, 2026, as disclosed in the explanation of responses.
How many derivative securities does the Relmada Therapeutics (RLMD) officer own after this transaction?
Following the reported transaction, the officer beneficially owns 828,000 derivative securitiesdirectly.
What common stock is underlying the Relmada Therapeutics (RLMD) stock appreciation rights grant?
The stock appreciation rights are linked to 828,000 sharesRelmada Therapeutics common stock
AI-generated analysis. How Rhea-AI works. Not financial advice.